{
    "clinical_study": {
        "@rank": "163021", 
        "arm_group": [
            {
                "arm_group_label": "Celecoxib", 
                "arm_group_type": "Active Comparator", 
                "description": "Celecoxib 200 mg by mouth, once a day for 6 weeks (Treatment Phase), followed by CG100649 2 mg, oral, for 18 weeks (Safety Phase)"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo capsule by mouth, once a day for 6 weeks (Treatment Phase), followed by CG100649 2 mg, oral, for 18 weeks (Safety Phase)"
            }, 
            {
                "arm_group_label": "CG100649", 
                "arm_group_type": "Experimental", 
                "description": "CG100649 2 mg capsule by mouth, once a day for 6 weeks (Treatment Phase); CG100649 2 mg capsule by mouth, once a day for 18 weeks (Safety Phase)"
            }
        ], 
        "brief_summary": {
            "textblock": "-  6-week Efficacy Study The objective of this study is to prove the safety and\n           non-inferiority of analgesic efficacy of CG100649 2 mg vs. celecoxib 200 mg, and\n           analgesic superiority of CG100649 2 mg vs. placebo, when administered once a day in\n           patients with osteoarthritis of the hip or knee over the 6 week Treatment period.  The\n           primary efficacy parameter is the difference from Baseline to Week 6 in the Western\n           Ontario and McMaster Universities Index of Osteoarthritis (WOMAC)-Pain subscale.\n\n        -  Extended Safety Study The objective of the Extended Safety Study is to collect a total\n           of 24 weeks of safety data for CG100649 including the initial 6 weeks of safety data,\n           and an additional 18 weeks of safety data for those subjects who agree on the consent\n           form to continue into the Extended Safety Study.  Subjects will be administered\n           CG100649 2 mg only during 18 weeks of Extended Safety Study."
        }, 
        "brief_title": "Phase III Study of CG100649 in Osteoarthritis Patients", 
        "completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Localized Primary Osteoarthritis of Hip", 
            "Localized Primary Osteoarthritis of Knee"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Osteoarthritis", 
                "Osteoarthritis, Hip", 
                "Osteoarthritis, Knee"
            ]
        }, 
        "detailed_description": {
            "textblock": "1. Number of Subjects: 350 (2:2:1 ratio of experimental vs. active comparator vs. placebo\n           comparator)\n\n        2. Adverse Events will be coded to preferred term and body system using the Medical\n           Dictionary for Regulatory Activities (MedDRA)"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria (abbreviated)\n\n          1. Males or females, age 20 years or above, able and willing to provide written informed\n             consent\n\n          2. Knee or Hip OA diagnosed according to American College of Rheumatology guidelines\n\n          3. Chronic pain for \u22653 months from OA\n\n          4. BP [systolic 90-140 mmHg, diastolic 50-90 mmHg] and pulse rate [resting 40-100 bpm].\n\n          5. WOMAC-Pain score in the index joint must be between 4-8 on a 0-10 numerical rating\n             scale\n\n          6. Blood chemistry must be within 2x normal range\n\n          7. Urinalysis must be within normal limits; minor deviations are acceptable\n\n          8. Subjects and their sexual partners must agree to use double barrier contraception\n             during the study period and for 3 months afterward, or be at least one year post-\n             menopause, or provide proof of surgical sterility\n\n          9. For prior non-steroidal inflammatory drug (NSAID) users only, the subject has a\n             history of positive therapeutic benefit\n\n         10. Subject is willing to limit alcohol intake to 2 or less drinks per day during study\n             and the follow-up period\n\n         11. Subjects must be able to read, understand and follow study related documents.\n\n        Exclusion Criteria (abbreviated)\n\n          1. Use of any analgesics except the study medication or acetaminophen at any time\n\n          2. Use of any medications for ongoing chronic symptoms, or psychiatric disorders that\n             could significantly diminish the cognitive ability or cause behavioral changes that\n             would prevent the subject from complying with study procedures.\n\n          3. Subject is legally incompetent, or has active psychosis, or significant emotional\n             problems which are sufficient to interfere with the conduct of the study\n\n          4. Use of anticoagulants (aspirin, warfarin, heparin, etc.) within 2 weeks of V1\n\n          5. Previous history of hypersensitivity or allergy to NSAIDs, COX-2 inhibitors, carbonic\n             anhydrase inhibitors, sulfa drugs, aspirin, or acetaminophen/paracetamol\n\n          6. Subjects requiring knee or hip arthroplasty within 2 months of screening or\n             anticipating any need for a surgical procedure on the index joint during the study\n\n          7. Diagnosed or treated for active GI ulcer, GI bleeding, ulcerative colitis, or severe\n             renal, hepatic, or coagulant disorder within 6 months prior to randomization\n\n          8. History of nasal polyps, bronchospasm, urticaria, or anaphylactic shock\n\n          9. Subjects who have had surgery on the affected joint within 6 months prior to the\n             study and subjects with a prosthesis at the index joint\n\n         10. Pregnant or breast-feeding, or expecting to conceive within the projected duration of\n             the study\n\n         11. Subjects who are currently participating or have participated in other clinical\n             studies within 4 weeks of screening or in any other clinical trial evaluating NSAIDs\n             or COX-2 inhibitors within 6 months of screening\n\n         12. Subjects who have received even one dose of rofecoxib or etoricoxib at any time in\n             their life\n\n         13. History of congestive heart failure with a status of New York Heart Association\n             II-IV, ischemic heart disease, uncontrolled hypertension, peripheral arterial\n             disease, cerebrovascular disease or subjects who have one of these diseases\n\n         14. Current user of recreational or illicit drugs or has had a recent history (1 year) of\n             drug or alcohol abuse or dependence\n\n         15. History of neoplastic disease or chemotherapy within 5 years of V1, with the\n             exception of non-metastatic skin cancer that has been completely cured\n\n         16. Subjects with gout, pseudogout, inflammatory arthritis, Paget's disease of bone,\n             chronic pain syndrome, fibromyalgia, or another major joint disease\n\n         17. Subjects using i.v, i.m., or oral corticosteroids, i.a. steroids or hyaluronic acid\n             injections within 1 month of V1\n\n         18. Subjects receiving a Chinese traditional arthritis treatment within 1 week of V1\n\n         19. Subjects who are not suitable to participate in the study by the investigator's\n             clinical decision"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "350", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 8, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01765296", 
            "org_study_id": "CG100649-3-01"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Celecoxib", 
                    "Placebo", 
                    "CG100649"
                ], 
                "description": "2 mg capsule", 
                "intervention_name": "CG100649", 
                "intervention_type": "Drug", 
                "other_name": "CG100649"
            }, 
            {
                "arm_group_label": "Celecoxib", 
                "description": "200 mg capsule", 
                "intervention_name": "Celecoxib", 
                "intervention_type": "Drug", 
                "other_name": "Celebrex"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Mimic for CG100649 2 mg capsule and for celecoxib 200 mg capsule", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug", 
                "other_name": "Placebo"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Celecoxib"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "April 27, 2013", 
        "location": [
            {
                "contact": {
                    "last_name": "Hee Soo Kyung, MD, PhD", 
                    "phone": "+82 53-200-0000"
                }, 
                "facility": {
                    "address": {
                        "city": "Daegu", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Kyungpook National University Hospital"
                }, 
                "investigator": {
                    "last_name": "Hee Soo Kyung, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Young Mo Kim, MD, PhD", 
                    "phone": "+82 53-200-0000"
                }, 
                "facility": {
                    "address": {
                        "city": "Daejeon", 
                        "country": "Korea, Republic of", 
                        "zip": "301-721"
                    }, 
                    "name": "Chungnam National University Hospital"
                }, 
                "investigator": {
                    "last_name": "Young Mo Kim, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Ju Hyung Yoo, MD, PhD", 
                    "phone": "+82 31-900-0000"
                }, 
                "facility": {
                    "address": {
                        "city": "Goyang-si", 
                        "country": "Korea, Republic of", 
                        "zip": "410-719"
                    }, 
                    "name": "NHIC Ilsan Hospital"
                }, 
                "investigator": {
                    "last_name": "Ju Hyung Yoo, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Beom Koo Lee, MD, PhD", 
                    "phone": "+82 32-460-0000"
                }, 
                "facility": {
                    "address": {
                        "city": "Incheon", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Gachon University Gil Medical Center"
                }, 
                "investigator": {
                    "last_name": "Beom Koo Lee, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Seong-Il Bin, MD, PhD", 
                    "phone": "+82 2 3010 0000"
                }, 
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "zip": "138-736"
                    }, 
                    "name": "Asan Medical Center"
                }, 
                "investigator": {
                    "last_name": "Seong-Il Bin, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Seung Baik Kang, MD, PhD", 
                    "phone": "+82 2-870-0000"
                }, 
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "zip": "156-707"
                    }, 
                    "name": "Boramae Medical Center"
                }, 
                "investigator": {
                    "last_name": "Seung Baik Kang, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Jong Oh Kim, MD, PhD", 
                    "phone": "+82 2 2650-0000"
                }, 
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "zip": "158-710"
                    }, 
                    "name": "Ewha Womans University Hospital"
                }, 
                "investigator": {
                    "last_name": "Jong Oh Kim, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Jin Goo Kim, MD, PhD", 
                    "phone": "+82 2-2270-0000"
                }, 
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Inje University Seoul Paik Hospital"
                }, 
                "investigator": {
                    "last_name": "Jin Goo Kim, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Choong Hyeok Choi, MD", 
                    "phone": "82 2-2290-0000"
                }, 
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "zip": "133-792"
                    }, 
                    "name": "Hanyang University Hospital"
                }, 
                "investigator": {
                    "last_name": "Choong Hyeok Choi, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Seung Beom Han, MD, PhD", 
                    "phone": "+82 2-920-0000"
                }, 
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Korea University Anam Hospital"
                }, 
                "investigator": {
                    "last_name": "Seung Beom Han, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Young Wan Moon, MD, PhD", 
                    "phone": "+82 2-3410-0000"
                }, 
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Samsung Medical Center"
                }, 
                "investigator": {
                    "last_name": "Young Wan Moon, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "In Yong, MD, PhD", 
                    "phone": "+82 2-2258-0000"
                }, 
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "zip": "137-701"
                    }, 
                    "name": "Seoul St. Mary's Hospital"
                }, 
                "investigator": {
                    "last_name": "In Yong, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Myung Chul Lee, MD, PhD", 
                    "phone": "+82 2 2072-0000"
                }, 
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "zip": "110-744"
                    }, 
                    "name": "Seoul National University Hospital"
                }, 
                "investigator": {
                    "last_name": "Myung Chul Lee, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Chong Hyuk Choi, MD, PhD", 
                    "phone": "+82 10 9016-0000"
                }, 
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "zip": "135-720"
                    }, 
                    "name": "Gangnam Severance Hospital"
                }, 
                "investigator": {
                    "last_name": "Chong Hyuk Choi, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Double-blind, Randomized, Multicenter, Active- and Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of CG100649 in Osteoarthritis Patients", 
        "other_outcome": {
            "description": "Adverse events (AEs)\nVital signs (BP, pulse rate, body temperature), 12-lead ECG\nClinical laboratory tests (hematology, chemistry, coagulation, urinalysis), physical examination", 
            "measure": "Safety Measures of Extended Safety Study", 
            "safety_issue": "Yes", 
            "time_frame": "24 weeks"
        }, 
        "overall_contact": {
            "email": "sjyang@cgxinc.com", 
            "last_name": "Su Jeong Yang"
        }, 
        "overall_contact_backup": {
            "email": "sgro@cgxinc.com", 
            "last_name": "Seonggu Ro, PhD"
        }, 
        "overall_official": [
            {
                "affiliation": "CrystalGenomics, Inc.", 
                "last_name": "Seonggu Ro, PhD", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "Seoul National University Hospital", 
                "last_name": "Myung Chul Lee, MD, PhD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Korea: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary efficacy outcome measure will be the change in the WOMAC-Pain Subscale in the index joint at W6 (Day 42) vs. Day 1 (Visit 2, pre-dose Baseline).", 
            "measure": "WOMAC-Pain Subscale in the index joint", 
            "safety_issue": "No", 
            "time_frame": "6 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01765296"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "\u2022 Change in the WOMAC OA index at W3 and W6 vs. pre-dose Baseline;", 
                "measure": "WOMAC Osteoarthritis (OA) Index", 
                "safety_issue": "No", 
                "time_frame": "Weeks 3 and 6"
            }, 
            {
                "description": "\u2022 Change in WOMAC OA subscales (pain, stiffness, physical function) at W3 and W6 vs. pre-dose Baseline;", 
                "measure": "WOMAC Osteoarthritis Subscales", 
                "safety_issue": "No", 
                "time_frame": "Weeks 3 and 6"
            }, 
            {
                "description": "\u2022 Subject's Global Assessment at W3 and W6 vs. pre-dose Baseline;", 
                "measure": "Subject's Global Assessment (SGA)", 
                "safety_issue": "No", 
                "time_frame": "Weeks 3 and 6"
            }, 
            {
                "description": "\u2022 Physician's Global Assessment at W3 and W6 vs. pre-dose Baseline;", 
                "measure": "Physician's Global Assessment (PGA)", 
                "safety_issue": "No", 
                "time_frame": "Weeks 3 and 6"
            }, 
            {
                "description": "\u2022 Withdrawals due to lack of analgesic efficacy.", 
                "measure": "Withdrawals", 
                "safety_issue": "No", 
                "time_frame": "Weeks 3 and 6"
            }
        ], 
        "source": "CrystalGenomics, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "CrystalGenomics, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2013"
    }
}